Chronic Obstructive Pulmonary Disorder (COPD)
The World Health Organisation (WHO) has described Chronic Obstructive Pulmonary Disorder (COPD) as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year.
What is Chronic Obstructive Pulmonary Disease?
Chronic obstructive pulmonary disease (COPD) is an assortment of lung disorders that includes...
The airways and lungs are affected by a range of diseases, but while some have been well characterized and treated, others such as chronic obstructive pulmonary disorder (COPD) are still somewhat of an enigma.
According to the latest research adults who do not smoke are at a greater risk of dying of serious lung disorders if they grew up around parents who smoked. The study appeared in the latest issue of the journal American Journal of Preventive Medicine.
A large study has found that removal of the tonsils as a child can mean that the individual is more susceptible to chest infections as an adult. The study appeared in the latest issue of the journal JAMA Otolaryngology Head and Neck Surgery.
About eight years ago the WHO put out a call saying that we needed data that better represented real world patients. Our ambition was to create evidence earlier in the life cycle of medicine that better represented the population that would...
A team of Vermont investigators has been issued a patent for their discovery of a molecule that rescues damaged blood vessels, yet preserves healthy vessels and could serve as a springboard for a new pharmaceutical therapy with fewer side effects for hypertension - a major risk factor for cardiovascular and kidney disease that effects roughly one in three people in the U.S.
Smokers who have chronic obstructive pulmonary disorder (COPD) may face nearly twice the risk of getting small cell lung cancer (SCLC)--the deadliest form of lung cancer--than smokers who don't have COPD, according to a large worldwide study led by researchers at the Harvard T.H. Chan School of Public Health.
People in the UK are living longer but are coping with more medical ailments causing illness or disability in their older years, according to a major new international study published in The Lancet today (Thursday 27 August).
Oxygen is delivered with variable flows that administer different concentrations. National guidelines were published in 2009 that provide recommendations about prescribing the oxygen and titrating it to certain target ranges.
With cancer rates rising worldwide, and Cancer Research UK predicting that the lifetime risk of cancer will reach 50% by 2027, the need for early diagnosis is overwhelming. Now, a British research group has published details of a simple empirical test to detect any early-stage cancer, relying on Andor's Komet software to automatically score the modified 3D 'Comet' assay results.
Epicure is a project led by Inventiva and Institut Curie that aims to deliver pre-clinical candidates on two novel epigenetic targets that have been selected due to their potential to activate immune responses against cancer cells. In addition one of these two targets has potential in respiratory indications such as asthma or COPD.
During a flare-up, symptoms of a patient’s COPD worsen significantly, and breathing becomes more difficult. A persistent increase in shortness of breath, cough and sputum production are typical symptoms.
In end-stage lung disease, transplantation is sometimes the only viable therapeutic option, but organ availability is limited and rejection presents an additional challenge.
The first thing is that we can’t cure COPD. The problem we have with COPD is that the process itself is not treatable, certainly not once it gets to the extent that it’s advanced.
Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.
Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine’s efficacy in treating asthma patients and is not currently approved for this indication.
Data from the olodaterol Phase 3 clinical program, presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, showed the addition of olodaterol 5 and 10 µg delivered once daily via the Respimat® inhaler provided improvements in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Novartis announced new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators1,2. These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.
Bethesda, MD-Japanese researchers have made a new step toward understanding why-and how to stop-runaway inflammation for both chronic obstructive pulmonary disorder (COPD) and allergic asthma. In a new report appearing in the August 2013 issue of The FASEB Journal scientists show that two receptors of an inflammatory molecule, called "leukotriene B4," play opposing roles in turning inflammation on and off for allergic asthma and COPD.
A group of Australian researchers, back in 2006, noted that there was a link between the severity of cystic fibrosis between sufferers who surfed, and sufferers who did not surf – and obviously Australia is a good place to spot that.